Schizophrenia: recent advances in LC-MS/MS methods to determine antipsychotic drugs in biological samples

Autor(es)

Queiroz, Maria Eugenia C. ^[1] ; Lemos Pinto, Monia Ap ^[2] ; Cruz, Jonas Carneiro ^[1] ; Ushirohira, Juliana Mayumi ^{[2, 3]} ; da Silva Dias, Isabella Caroline ^{[2, 3]} ; Hallak, Jaime E. C. ^{[2, 3]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept Quim, Ave Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP - Brazil

^[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Sao Paulo - Brazil

^[3] CNPQ FAPESP CAPES, Translat Med INCT TM, Natl Inst Sci & Technol, Sao Paulo - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: BIOANALYSIS; v. 11, n. 3, p. 215-231, FEB 2019.
• Citações Web of Science: 1

Resumo

Schizophrenia is one of the most debilitating and costly illnesses worldwide. First-generation antipsychotics such as chlorpromazine and haloperidol succeeded in controlling the positive symptoms of schizophrenia, but had significant extrapyramidal effects that led to the search for new agents and the release of second-generation (or atypical) antipsychotics. These drugs had a lower risk of adverse motor symptoms. Therapeutic drug monitoring has become a useful tool to optimize schizophrenia treatment and HPLC-MS/MS has been considered the primary technique to monitor antipsychotics. This review comprises three sections: schizophrenia pathophysiology and treatment; recent advances in LC-MS/MS methods designed to measure levels of antipsychotics and their metabolites in plasma samples (selectivity, matrix effect and sensitivity); and the importance of therapeutic drug monitoring. (AU)

• Processo FAPESP: 17/02147-0 - Cromatografia líquida em uma gota e seu acoplamento com espectrometria de massas: estratégias instrumentais, desenvolvimento de materiais, automatização e aplicações analíticas
• Beneficiário: Fernando Mauro Lanças
• Modalidade de apoio: Auxílio à Pesquisa - Temático